CELL INTELLIGENCE · 肿瘤细胞治疗研究

Inclusion Criteria:

* participants treated with CART-Cell therapy as described above and therefore at risk for treatment associated neurotoxicity.
* Visual acuity of 20/100 or better.

Exclusion Criteria:

* patients \< 18 years old
* pregnant women
* prisoners
* adults unable to consent,
* participants unwilling to use iPad-based tools. Severe motor deficits that can prevent patients from using an iPad

主要终点：Sensitivity of DCog Short for Early Detection of Neurotoxicity · Neurotoxicity is defined as any decrease from 10 on the Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) 10-point scale, where 10 indicates no impairment. The DCog Short assessment will be compared with the standard clinical ICANS evaluation to determine its ability to detect neurotoxicity on or before the onset of clinically confirmed ICANS. Sensitivity is defined as the proportion of patients with clinically confirmed ICANS for whom DCog Short indicates neurotoxicity on or before ICANS onset. DCog Short will be considered effective if sensitivity is ≥75% and non-promising if sensitivity is \<50%. · Until 30 days post CAR T-cell infusion, with frequency as described in the protocol schedule section 10.0.；Specificity of DCog Short for Early Detection of Neurotoxicity · Neurotoxicity is defined as any decrease from 10 on the Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) 10-point scale, where 10 indicates no impairment. The DCog Short assessment will be compared with the standard clinical ICANS evaluation to determine its ability to correctly identify patients who do not develop neurotoxicity. Specificity is defined as the proportion of patients who do not develop clinically confirmed ICANS and are not indicated by DCog Short. DCog Short will be considered effective if specificity is ≥75% and non-promising if specificity is \<50%. · Until 30 days post CAR T-cell infusion, with frequency as described in the protocol schedule section 10.0.；Positive Predictive Value (PPV) of DCog Short for Early Detection of Neurotoxicity · Neurotoxicity is defined as any decrease from 10 on the Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) 10-point scale, where 10 indicates no impairment. The DCog Short assessment will be compared with the standard clinical ICANS evaluation to determine its ability to correctly identify patients who do not develop neurotoxicity. Positive predictive value is defined as the proportion of patients indicated by DCog Short who subsequently develop Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) based on standard clinical assessment. · Until 30 days post CAR T-cell infusion, with frequency as described in the protocol schedule section 10.0.；Negative Predictive Value (NPV) of DCog Short for Early Detection of Neurotoxicity · Neurotoxicity is defined as any decrease from 10 on the Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) 10-point scale, where 10 indicates no impairment. The DCog Short assessment will be compared with the standard clinical ICANS evaluation to determine its ability to correctly identify patients who do not develop neurotoxicity. Negative predictive value is defined as the proportion of patients not indicated by DCog Short who do not develop Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) based on standard clinical assessment. · Until 30 days post CAR T-cell infusion, with frequency as described in the protocol schedule section 10.0.；Raw Accuracy of DCog Short for Early Detection of Neurotoxicity · Neurotoxicity is defined as any decrease from 10 on the Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) 10-point scale, where 10 indicates no impairment. The DCog Short assessment will be compared with the standard clinical ICANS evaluation to determine its ability to correctly identify patients who do not develop neurotoxicity. Raw accuracy is defined as the proportion of patients correctly classified by DCog Short, including both patients who develop Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) and those who do not, based on standard clinical assessment. · Until 30 days post CAR T-cell infusion, with frequency as described in the protocol schedule section 10.0.
次要终点：Immune Effector Cell-Associated Encephalopathy (CARTOX-10) Score Change from Baseline；Differences in Neurotoxicity Development and Detection Across CAR T-Cell Therapy Types

• CAR-T Cell Therapy Patients · EXPERIMENTAL · 40 enrolled participants will complete: * Baseline visit * Daily study visits during hospitalization, then via phone: 2x weekly on days 14 - 21, then weekly on days 21 - 30 * 90 Day follow up visit

The aim of this study is to determine the effectiveness of DCog Short, a self-reporting, iPad-based application tool, in assessing neurotoxicity in participants undergoing CAR-T cell therapy.